Top Markets
#1 Bedrock Bedrock +51.79%
#2 pippin pippin +19.58%
#3 IQ IQ +19.18%
#4 Naoris Protocol Naoris Protocol +18.03%
#5 Irys Irys +17.31%
#6 ETHGas ETHGas +16.17%
#7 Aria.AI Aria.AI +14.78%
#8 Buttcoin Buttcoin +14.36%
#9 Magma Finance Magma Finance +14.06%
#10 DUSK Network DUSK Network +11.60%
Coin of the day
Bedrock Bedrock
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Kedudukan dalam Saham #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Harga Saham
$0.16328419
Modal Pasaran
$204.14K
Perubahan (1 hari)
4.35%
Perubahan (1 tahun)
102.45%
Negara
GB
Perdagangan Fusion Antibodies plc (FAB)

Kategori

Healthcare
Nisbah P/E bagi Fusion Antibodies plc (FAB)
Nisbah P/E pada March 2026 TTM: -9.65
Menurut laporan kewangan dan harga saham terkini Fusion Antibodies plc, nisbah P/E semasa (TTM) ialah -9.65. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak -0.96.
Sejarah nisbah P/E bagi Fusion Antibodies plc dari 2013 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) -9.65 180.42%
2025 -3.44 258.24%
2024 -0.96 -75.09%
2023 -3.86 -70.26%
2022 -12.97 -5.91%
2021 -13.79 -54.21%
2020 -30.11 504.68%
2019 -4.98 -79.50%
2018 -24.29 -110.68%
2017 227.44 862.11%
2016 23.64 -107.37%
2015 -320.55 33.40%
2014 -240.30 312.85%
2013 -58.20 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 10.72 -211.10%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 30.14 -412.49%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 17.03 -276.59%
US
UCB SA UCB SA
UCB SA
UCB.BR
 30.44 -415.54%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 38.30 -497.06%
NL
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.